Related Experiment Video
Updated: Aug 20, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Characteristics, Antithrombotic Patterns, and Prognostic Outcomes in Claudication and Critical Limb-Threatening
Osami Kawarada1,2, Kan Zen3,4, Koji Hozawa5
1Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Insights
Critical limb-threatening ischemia (CLTI) patients exhibit more comorbidities and inflammatory issues than intermittent claudication (IC) patients. CLTI also shows double the adverse cardiovascular events and reintervention rates, linked to inflammatory coagulation disorders.
Area of Science:
- Vascular Surgery
- Peripheral Artery Disease
- Endovascular Therapy
Background:
- Intermittent claudication (IC) and critical limb-threatening ischemia (CLTI) are distinct stages of peripheral artery disease (PAD).
- The precise clinical and prognostic differences between IC and CLTI remain incompletely understood.
- Understanding these differences is crucial for optimizing treatment strategies in PAD.
Purpose of the Study:
- To delineate the clinical characteristics differentiating IC from CLTI.
- To compare prognostic outcomes, including major adverse cardiovascular events (MACE) and reintervention rates, between IC and CLTI patients undergoing endovascular therapy (EVT).
- To identify prognostic factors associated with MACE and reintervention in patients treated with EVT.
Main Methods:
- Prospective, multicenter observational study (JPASSION study) involving 692 patients (808 limbs) from 20 Japanese institutions.
- Patients were categorized into IC (79.0%) and CLTI (21.0%) groups.
- Primary endpoints were 3-year rates of MACE and reintervention, with secondary analyses of clinical features, disease distribution, and prognostic factors.
Main Results:
- CLTI patients presented with more comorbidities, impaired functional status, undernutrition, hypercoagulation, hyperinflammation, and distal artery disease compared to IC patients.
- Infrapopliteal disease was dominant in CLTI, necessitating more infrainguinal interventions, while IC predominantly involved aortoiliac and femoropopliteal disease.
- Three-year MACE rates were significantly higher in CLTI (42.3%) versus IC (20.4%), as were reintervention rates (46.8% vs. 22.1%).
- Elevated D-dimer, age, impaired functional status, and end-stage renal disease independently predicted MACE.
- Elevated erythrocyte sedimentation rate and infrainguinal intervention were independently associated with reintervention.
Conclusions:
- CLTI is distinguished by a greater burden of systemic comorbidities, distal vascular disease, and a more pronounced inflammatory coagulation disorder compared to IC.
- CLTI patients experience approximately double the rates of MACE and reintervention following EVT.
- The underlying inflammatory coagulation disorder appears to be an independent predictor of adverse outcomes in PAD patients undergoing EVT.
Purpose:
The underlying difference between intermittent claudication (IC) and critical limb-threatening ischemia (CLTI) still remains unclear. This prospective multicenter observational study aimed to clarify differences in clinical features and prognostic outcomes between IC and CLTI, and prognostic factors in patients undergoing endovascular therapy (EVT).
Materials And Methods:
A total of 692 patients with 808 limbs were enrolled from 20 institutions in Japan. The primary measurements were the 3-year rates of major adverse cardiovascular event (MACE) and reintervention.
Results:
Among patients, 79.0% had IC and 21.0% had CLTI. Patients with CLTI were more frequently women and more likely to have impaired functional status, undernutrition, comorbidities, hypercoagulation, hyperinflammation, distal artery disease, short single antiplatelet and long anticoagulation therapies, and late cilostazol than patients with IC. Aortoiliac and femoropopliteal diseases were dominant in patients with IC and infrapopliteal disease was dominant in patients with CLTI. Patients with CLTI underwent less frequently aortoiliac intervention and more frequently infrapopliteal intervention than patients with IC. Longitudinal change of ankle-brachial index (ABI) exhibited different patterns between IC and CLTI (pinteraction=0.002), but ABI improved after EVT both in IC and in CLTI (p<0.001), which was sustained over time. Dorsal and plantar skin perfusion pressure in CLTI showed a similar improvement pattern (pinteraction=0.181). Distribution of Rutherford category improved both in IC and in CLTI (each p<0.001). Three-year MACE rates were 20.4% and 42.3% and 3-year reintervention rates were 22.1% and 46.8% for patients with IC and CLTI, respectively (log-rank p<0.001). Elevated D-dimer (p=0.001), age (p=0.043), impaired functional status (p=0.018), and end-stage renal disease (p=0.019) were independently associated with MACE. After considering competing risks of death and major amputation for reintervention, elevated erythrocyte sedimentation rate (p=0.003) and infrainguinal intervention (p=0.002) were independently associated with reintervention. Patients with CLTI merely showed borderline significance for MACE (adjusted hazard ratio 1.700, 95% confidence interval 0.950-3.042, p=0.074) and reintervention (adjusted hazard ratio 1.976, 95% confidence interval 0.999-3.909, p=0.05).
Conclusions:
The CLTI is characterized not only by more systemic comorbidities and distal disease but also by more inflammatory coagulation disorder compared with IC. Also, CLTI has approximately twice MACE and reintervention rates than IC, and the underlying inflammatory coagulation disorder per se is associated with these outcomes.
Clinical Impact:
The underlying difference between intermittent claudication (IC) and critical limb-threatening ischemia (CLTI) still remains unclear. This prospective multicenter observational study, JPASSION study found that CLTI was characterized not only by more systemic comorbidities and distal disease but also by more inflammatory coagulation disorder compared to IC. Also, CLTI had approximately twice major adverse cardiovascular event (MACE) and reintervention rates than IC. Intriguingly, the underlying inflammatory coagulation disorder per se was independently associated with MACE and reintervention. Further studies to clarify the role of anticoagulation and anti-inflammatory therapies will contribute to the development of post-interventional therapeutics in the context of peripheral artery disease.
More Related Videos
07:48Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Venous Thrombosis IV: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies